Table 5.
Exposed | Unexposed | Crude | Adjustedb | |||||
---|---|---|---|---|---|---|---|---|
Medication Exposurea | Cases | Controls | Cases | Controls | OR | 95% CI | OR | 95% CI |
Antihistamine Antiemetics | 43 | 211 | 668 | 3805 | 1.16 | 0.83–1.63 | 1.24 | 0.87–1.78 |
Doxylamine | 7 | 38 | 704 | 3978 | 1.04 | 0.46–2.34 | 1.05 | 0.46–2.43 |
Promethazine | 35 | 161 | 676 | 3855 | 1.24 | 0.85–1.80 | 1.39 | 0.94–2.06 |
Other Antihistamine | 17 | 97 | 694 | 3919 | 0.99 | 0.59–1.67 | 0.99 | 0.58–1.71 |
Diphenhydramine | 16 | 68 | 695 | 3947 | 1.32 | 0.76–2.28 | 1.32 | 0.74–2.34 |
antihistamine antiemetics plus B6 combinations: | ||||||||
Doxylamine plus pyridoxine | 6 | 19 | 705 | 3997 | 1.78 | 0.71–4.45 | 1.84 | 0.71–4.78 |
Phenothiazines (other than Promethazine) | 4 | 16 | 707 | 4000 | 1.41 | 0.47–4.24 | 1.59 | 0.51–4.96 |
Prochlorperazine | 4 | 16 | 707 | 4000 | 1.41 | 0.47–4.24 | 1.59 | 0.51–4.96 |
5HT3 antagonists | 4 | 46 | 707 | 3970 | 0.49 | 0.18–1.36 | 0.58 | 0.21–1.64 |
Ondansetron | 4 | 44 | 707 | 3972 | 0.51 | 0.18–1.43 | 0.60 | 0.21–1.68 |
Emetrol/Coke syrup | 5 | 22 | 706 | 3994 | 1.29 | 0.49–3.41 | 1.46 | 0.54–3.94 |
Phosphorated Carbohydrate Solution | 5 | 21 | 706 | 3995 | 1.34 | 0.51–3.58 | 1.53 | 0.57–4.16 |
Bismuth subsalicylate | 7 | 15 | 704 | 4001 | 2.65 | 1.08–6.53 | 2.37 | 0.90–6.21 |
Antacids | 29 | 198 | 682 | 3818 | 0.82 | 0.55–1.22 | 0.92 | 0.61–1.39 |
Calcium Carbonate | 20 | 153 | 691 | 3863 | 0.73 | 0.46–1.17 | 0.87 | 0.54–1.42 |
Aluminum Magnesium Hydroxide/Simethicone | 4 | 29 | 707 | 3987 | 0.78 | 0.27–2.22 | 0.61 | 0.19–1.96 |
H2 Blockers | 8 | 29 | 703 | 3987 | 1.56 | 0.71–3.44 | 1.80 | 0.80–4.05 |
Ranitidine | 4 | 21 | 707 | 3995 | 1.08 | 0.37–3.14 | 1.28 | 0.43–3.82 |
Pyridoxine | 14 | 98 | 697 | 3918 | 0.80 | 0.46–1.41 | 0.75 | 0.42–1.34 |
Herbal/Natural products | 22 | 119 | 689 | 3897 | 1.05 | 0.66–1.66 | 1.14 | 0.70–1.83 |
Used alone or in combination with other agents; categories are not mutually exclusive. Missing data on medication exposure (<0.7% of subjects) were grouped with the unexposed.
Adjusted for maternal age, race/ethnicity and education, parity, plurality, previous miscarriage, any smoking in the month before conception through the first trimester, body mass index, infant sex, any folic acid use in the month before conception through the first trimester, use of unknown antiemetic, site, and expected year of delivery. N=711 NTD cases (634 (89.2%) isolated, 76 (10.7%) multiple, and 1 (0.1%) complex defects) and 4016 controls.